A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modes...

Descripción completa

Detalles Bibliográficos
Autores principales: Heudobler, Daniel, Schulz, Christian, Fischer, Jürgen R., Staib, Peter, Wehler, Thomas, Südhoff, Thomas, Schichtl, Thomas, Wilke, Jochen, Hahn, Joachim, Lüke, Florian, Vogelhuber, Martin, Klobuch, Sebastian, Pukrop, Tobias, Herr, Wolfgang, Held, Swantje, Beckers, Kristine, Bouche, Gauthier, Reichle, Albrecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007965/
https://www.ncbi.nlm.nih.gov/pubmed/33796020
http://dx.doi.org/10.3389/fphar.2021.599598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007965/
https://www.ncbi.nlm.nih.gov/pubmed/33796020
http://dx.doi.org/10.3389/fphar.2021.599598

Ejemplares similares